Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.59|
|52 Week High||US$13.04|
|52 Week Low||US$29.80|
|1 Month Change||16.34%|
|3 Month Change||-18.80%|
|1 Year Change||-24.83%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||76.49%|
Recent News & Updates
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|APLT||US Biotechs||US Market|
Return vs Industry: APLT underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: APLT underperformed the US Market which returned 30% over the past year.
Stable Share Price: APLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: APLT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.
Applied Therapeutics Fundamentals Summary
|APLT fundamental statistics|
Is APLT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APLT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.96|
|Net Profit Margin||0.00%|
How did APLT perform over the long term?See historical performance and comparison
Is Applied Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APLT ($16.59) is trading below our estimate of fair value ($79.51)
Significantly Below Fair Value: APLT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APLT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: APLT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APLT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APLT is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (2.9x).
How is Applied Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APLT's revenue (73.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: APLT's revenue (73.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APLT is forecast to be unprofitable in 3 years.
How has Applied Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APLT is currently unprofitable.
Growing Profit Margin: APLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APLT is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.
Accelerating Growth: Unable to compare APLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: APLT has a negative Return on Equity (-92.08%), as it is currently unprofitable.
How is Applied Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: APLT's short term assets ($135.3M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: APLT's short term assets ($135.3M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: APLT's debt to equity ratio (2.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if APLT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: APLT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 62.1% each year.
What is Applied Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shoshana Shendelman (42 yo)
Dr. Shoshana Shendelman, PhD, has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, she founded Clearpoint Strategy Group, a boutique strategic advisory firm in NYC,...
CEO Compensation Analysis
Compensation vs Market: Shoshana's total compensation ($USD4.57M) is above average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Shoshana's compensation has been consistent with company performance over the past year.
Experienced Management: APLT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: APLT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: APLT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.
Applied Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Applied Therapeutics, Inc.
- Ticker: APLT
- Exchange: NasdaqGM
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$434.290m
- Shares outstanding: 26.18m
- Website: https://www.appliedtherapeutics.com
Number of Employees
- Applied Therapeutics, Inc.
- 545 Fifth Avenue
- Suite 1400
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:52|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.